ofloxacin has been researched along with Disease, Pulmonary in 19 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 5.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| "Imipenem, levofloxacin or saline were administered to rats with caerulein induced pancreatitis." | 3.73 | Effects of selected antibiotics on pancreatitis induced liver and pulmonary injury. ( Coker, A; Coker, C; Erkan, N; Onek, T; Sağol, O; Zeytunlu, M, 2005) |
| "Ofloxacin was used in the treatment of 124 patients with bronchopulmonary diseases, the diseases of the biliary system and other infectious inflammatory diseases of the internal organs." | 2.68 | [Clinico-pharmacologic aspects of the use of ofloxacin]. ( Belitskaia, RA; Dubova, MN; Krasavina, MIu; Kukes, VG; Posrednikova, TA, 1996) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 1.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| " The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection." | 1.35 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. ( Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009) |
| "Actinomycosis is a chronic suppurative bacterial infection characterized by multiple abscesses, fistulous pathways, and fibrosis involving the face, neck, chest, and abdomen." | 1.35 | Treatment of pulmonary actinomycosis with levofloxacin. ( Amado, J; Carvalho, A; Ferreira, Dde F; Neves, S; Nogueira, R; Taveira, N, 2008) |
| "We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung." | 1.28 | Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. ( Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991) |
| "Pulmonary nocardiosis is a rare disease." | 1.28 | [A case of pulmonary nocardiosis associated with middle lobe atelectasis]. ( Katoh, O; Kuroki, S; Nagasawa, Z; Nakanishi, Y; Yamada, H; Yamaguchi, M, 1990) |
| "A 58-year-old man with pulmonary disease due to Mycobacterium fortuitum was treated successfully with ofloxacin (0." | 1.27 | Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum. ( Ichiyama, S; Tsukamura, M, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sabet, M | 1 |
| Miller, CE | 1 |
| Nolan, TG | 1 |
| Senekeo-Effenberger, K | 1 |
| Dudley, MN | 2 |
| Griffith, DC | 2 |
| King, P | 1 |
| Lomovskaya, O | 1 |
| Burns, JL | 1 |
| Fernández-Olmos, A | 1 |
| García-Castillo, M | 1 |
| Maiz, L | 1 |
| Lamas, A | 1 |
| Baquero, F | 1 |
| Cantón, R | 1 |
| Moretti, F | 1 |
| Quiros-Roldan, E | 1 |
| Casari, S | 1 |
| Viale, P | 1 |
| Chiodera, A | 1 |
| Carosi, G | 1 |
| Watson, AM | 1 |
| Boyce, TG | 1 |
| Wylam, ME | 1 |
| Onek, T | 1 |
| Erkan, N | 1 |
| Zeytunlu, M | 1 |
| Sağol, O | 1 |
| Coker, C | 1 |
| Coker, A | 1 |
| Shitrit, D | 1 |
| Baum, GL | 1 |
| Priess, R | 1 |
| Lavy, A | 1 |
| Shitrit, AB | 1 |
| Raz, M | 1 |
| Shlomi, D | 1 |
| Daniele, B | 1 |
| Kramer, MR | 1 |
| Ferreira, Dde F | 1 |
| Amado, J | 1 |
| Neves, S | 1 |
| Taveira, N | 1 |
| Carvalho, A | 1 |
| Nogueira, R | 1 |
| Fukuoka, Y | 1 |
| Ikeda, Y | 1 |
| Yamashiro, Y | 1 |
| Takahata, M | 1 |
| Todo, Y | 1 |
| Narita, H | 1 |
| Kukes, VG | 1 |
| Belitskaia, RA | 1 |
| Dubova, MN | 1 |
| Krasavina, MIu | 1 |
| Posrednikova, TA | 1 |
| Weber, C | 1 |
| Maas, R | 1 |
| Steiner, P | 1 |
| Kramer, J | 1 |
| Bumann, D | 1 |
| Zander, AR | 1 |
| Bücheler, E | 1 |
| Schreiber, J | 1 |
| Burkhardt, U | 1 |
| Rüsch-Gerdes, S | 1 |
| Amthor, M | 1 |
| Richter, E | 1 |
| Zugehör, M | 1 |
| Rosahl, W | 1 |
| Ernst, M | 1 |
| Marcos Sánchez, F | 1 |
| Aparicio Martínez, JC | 1 |
| Celdrán Gil, J | 1 |
| Durán Pérez-Navarro, A | 1 |
| Vallée, E | 1 |
| Azoulay-Dupuis, E | 1 |
| Pocidalo, JJ | 1 |
| Bergogne-Bérézin, E | 1 |
| Yamaoka, M | 1 |
| Fukuchi, Y | 1 |
| Yokouchi, M | 1 |
| Teramoto, N | 1 |
| Nagase, T | 1 |
| Ishida, K | 1 |
| Ohtomo, E | 1 |
| Orimo, H | 1 |
| Kuroki, S | 1 |
| Yamada, H | 1 |
| Katoh, O | 1 |
| Nakanishi, Y | 1 |
| Yamaguchi, M | 1 |
| Nagasawa, Z | 1 |
| Nakamura, S | 1 |
| Minami, A | 1 |
| Nakata, K | 1 |
| Kurobe, N | 1 |
| Kouno, K | 1 |
| Sakaguchi, Y | 1 |
| Kashimoto, S | 1 |
| Yoshida, H | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
| Ichiyama, S | 1 |
| Tsukamura, M | 1 |
| Noel, F | 1 |
| Couet, W | 1 |
| Lefebvre, MA | 1 |
| Akbaraly, JP | 1 |
| Mignot, A | 1 |
| Fourtillan, JB | 1 |
1 trial available for ofloxacin and Disease, Pulmonary
| Article | Year |
|---|---|
[Clinico-pharmacologic aspects of the use of ofloxacin].
Topics: Anti-Infective Agents; Antibody Formation; Bacterial Infections; Biliary Tract Diseases; Bronchial D | 1996 |
18 other studies available for ofloxacin and Disease, Pulmonary
| Article | Year |
|---|---|
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Ani | 2009 |
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, M | 2010 |
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin; | 2012 |
Rhodococcus equi: pulmonary cavitation lesion in patient infected with HIV cured by levofloxacin and rifampicin.
Topics: Actinomycetales Infections; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Ant | 2002 |
Legionella pneumonia: infection during immunosuppressive therapy for idiopathic pulmonary hemosiderosis.
Topics: Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hemosiderosis; Humans; Immunosuppressiv | 2004 |
Effects of selected antibiotics on pancreatitis induced liver and pulmonary injury.
Topics: Acute Disease; Alanine Transaminase; Amylases; Animals; Anti-Bacterial Agents; Aspartate Aminotransf | 2005 |
Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Topics: Adult; Antibiotics, Antitubercular; Ciprofloxacin; Clarithromycin; Cycloserine; Ethambutol; Ethionam | 2006 |
Treatment of pulmonary actinomycosis with levofloxacin.
Topics: Actinomycosis; Anti-Bacterial Agents; Diagnosis, Differential; Female; Humans; Levofloxacin; Lung Di | 2008 |
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases | 1993 |
[Importance of digital thoracic radiography in the diagnosis of pulmonary infiltrates in patients with bone marrow transplantation during aplasia].
Topics: Adult; Anemia, Aplastic; Anti-Infective Agents; Antibiotic Prophylaxis; Antifungal Agents; Bone Marr | 1999 |
[Non-tubercular mycobacterial infection of the lungs due to Mycobacterium smegmatis].
Topics: Cardiopulmonary Resuscitation; CD4-Positive T-Lymphocytes; Clarithromycin; Drug Therapy, Combination | 2001 |
[Ofloxacin in the treatment of lower respiratory tract infections in patients with chronic pulmonary diseases].
Topics: Chronic Disease; Humans; Lung Diseases; Ofloxacin; Respiratory Tract Infections | 1992 |
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseas | 1991 |
Efficacy of oral administration of ofloxacin in lower respiratory tract infections in aged patients with chronic lung disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Chronic Disease; Fe | 1991 |
[A case of pulmonary nocardiosis associated with middle lobe atelectasis].
Topics: Aged; Drug Combinations; Drug Therapy, Combination; Female; Gentamicins; Humans; Lung Diseases; Noca | 1990 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |
Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum.
Topics: Humans; Lung Diseases; Male; Middle Aged; Mycobacterium Infections; Ofloxacin; Oxazines; Radiography | 1987 |
Diffusion of ofloxacin in human tissues.
Topics: Administration, Oral; Adult; Female; Humans; Lung Diseases; Male; Middle Aged; Nephrectomy; Ofloxaci | 1987 |